NASDAQ: ALLR - Allarity Therapeutics, Inc.

Yield per half year: +19.42%
Sector: Healthcare

Share chart Allarity Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.

More details
Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Выручка 0.00012
EBITDA -0.0101
P/BV 3.51
EV/EBITDA 0.0558
Цена ао 0.309
ISIN US0167441049
Число акций ао 9.95E-5 млрд
Сайт https://www.allarity.com
Валюта usd
IPO date 2021-12-21
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: +16.08% (1.43)
Change price per week: +12.93% (1.47)
Change price per month: -50.89% (3.38)
Change price per 3 month: +790.08% (0.1865)
Change price per half year: +19.42% (1.39)
Change price per year: +127.4% (0.73)
Change price per year to date: +235.35% (0.495)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -11.88 0
P/E 0 0
EV/EBITDA -1.89 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -100.33 0
ROE, % 432.61 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0727 10
Total: 8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 77.15 8
Yield EPS, % 7.55 1
Total: 2.6
More

Institutions Volume Share, %
Sabby Management, LLC 359400 7.45
Armistice Capital, LLC 261000 5.41
Citadel Advisors Llc 26215 0.54
Virtu Financial LLC 25795 0.53
TWO SIGMA SECURITIES, LLC 12587 0.26
Tower Research Capital LLC (TRC) 5591 0.12
Wells Fargo & Company 6 0



Head Job title Payment Year of birth
Mr. Thomas H. Jensen Founder, CEO & Director N/A 1978 (46 years)
Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. Co-Founder 546.08k 1955 (69 years)
Dr. Steen Meier Knudsen Ph.D. Founder & Chief Scientific Officer 185.11k 1961 (63 years)
Mr. Alexander Epshinsky Chief Financial Officer 1983 (41 year)

Address: United States, Boston. MA, 24 School Street - open in Google maps, open in Yandex maps
Website: https://www.allarity.com